Aspira Womens HealthAWHL -4.04%36 Days Payable is 163.20 as of Mar. 2026, which is 50% above its 10-year median of 108.62. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Aspira Womens Health ranks better than 77.89% on this metric.
The historical rank and industry rank for Aspira Womens Health's Days Payable or its related term are showing as below:
AWHL'
s Days Payable Range Over the Past 10 Years
Min: 98.45 Med: 108.62 Max: 188.53
Current: 172.32
During the past 13 years, Aspira Womens Health's highest Days Payable was 188.53. The lowest was 98.45. And the median was 108.62.
AWHL's Days Payable is ranked better than 77.89% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs AWHL: 172.32
Aspira Womens Health's Days Payable
declined
from Mar. 2025 (229.97) to Mar. 2026 (163.20).
It may suggest that Aspira Womens Healthaccelerated paying its suppliers.
Aspira Womens Health Days Payable Related Terms
Aspira Womens Health Days Payable Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Aspira Womens Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aspira Womens Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a Days Payable of 163.20 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aspira Womens Health and its competitors. This is 50% above median its historical median of 108.62. Over the past decade, Aspira Womens Health's Days Payable has ranged from 98.45 to 188.53. According to the industry distribution chart, Aspira Womens Health ranks #42 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 22.1%.
Is Aspira Womens Health's Days Payable too high?
Aspira Womens Health's current Days Payable of 163.20 is 50% above median its 10-year median of 108.62. Over the past 10 years, this metric has ranged from a low of 98.45 to a high of 188.53. The Medical Diagnostics & Research industry median Days Payable is 67.28. Aspira Womens Health's value of 163.20 is 142.6% above this industry median. Based on the distribution chart, Aspira Womens Health ranks #42 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Days Payable compare to MDXH and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #42 out of 190 companies for Days Payable. This places Aspira Womens Health in the top 22% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.28. Aspira Womens Health's value of 163.20 is 142.6% above this benchmark. Historically, Aspira Womens Health's own Days Payable has ranged from 98.45 to 188.53 over the past decade. While the company's 10-year median is 108.62 vs. the industry median of 67.28, Aspira Womens Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Womens Health's current Days Payable of 163.20 is 142.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current Days Payable is 163.20, which is 50% above median its own 10-year median of 108.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.43 — trading 53.6% above its estimated fair value. The current Days Payable is 163.20, which is 50% above median its 10-year median of 108.62 and 142.6% above the Medical Diagnostics & Research industry median of 67.28. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Days Payable is 163.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.43 is trading 53.6% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
Days Payable: 163.20 (50% above median its 10-year median of 108.62)
GF Value™: $0.28 vs. price of $0.43 (53.6% above fair value)
Industry Position: 142.6% above the Medical Diagnostics & Research median (#42 of 190)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score
Get the complete analysis for AWHL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
